Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.
about
Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available dataThe fate of chemoresistance in triple negative breast cancer (TNBC)The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectivesRole of positron emission tomography for the monitoring of response to therapy in breast cancerAdditional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancerTBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional studyStratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant ChemotherapyPredictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatmentTriple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Whole-body 18FDG-PET/CT or whole-body gadolinium-enhanced MRI for distant staging?Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
P2860
Q26769835-397821E1-4298-4809-9903-D419C460B7F4Q26775232-D78DA3B3-40AF-4021-9407-A34C4ABD2CF7Q28077678-CE4111BE-9B75-430B-856B-DF77A6A84F32Q28080621-7B5FE126-A477-461A-8DFC-0975FFED61C8Q33730822-29A1C3B9-44BC-4F0B-AE95-6BCCD558E270Q35155635-A65F0901-7913-4975-B946-DE1C9C57503CQ35539538-DE2BE36A-4B42-4AC9-B59D-56A8EEBB85A1Q36109265-D2A6CA76-CB81-49EE-9905-B77A3D855100Q36364739-E5B0A24C-E58F-4066-9310-D68DC7EDD9C9Q36476568-AFB3B82C-4C76-4445-A3AC-A77C53C660CEQ36734702-38DCB8CC-5FCF-4A72-8709-A811BC99CA55Q37077266-63DEC6B1-7BF7-49BE-940A-283236A52B9EQ37105085-CC28FEAD-93E0-4B6E-81A4-081CFDBE608DQ37176151-F51F91B3-031C-42EA-A627-DE128BDED449Q37185872-59C6D6E4-6BFE-432B-871F-011FE23F9B14Q37252097-D6B57C17-C7FB-44A1-8B21-CDAD90783B0FQ38059133-948112C7-F8EC-40B2-BDE8-6FF1B042DAB2Q38165388-7D5F6530-4F0E-4AB4-9413-9D90C3E599A9Q38190005-29548F6F-0CBB-4BE4-9BEB-FFF4FDA2CDD5Q38426713-CA6E07F9-1474-4716-B60E-B306C601D7AEQ38693888-73A78231-708A-4621-86C4-CDC295F5890AQ40852747-2DE145CD-FE85-49CD-B2CB-F48BB186AFF4Q43082312-81312503-65A7-48E6-A662-6589AB2DCDCDQ46014390-F125E417-B499-45A5-A31B-8F4FF85F4B23Q47822633-79E56685-3662-4B68-88AF-7AA585867516Q47856252-9F969477-0C6A-4624-8F6B-05684D48C1A6Q48444536-78C25951-4570-4B56-B3A2-95F5A484C7FFQ52584340-C5DDF703-B4AC-4337-8C76-E776857CD976Q53116763-998F13BA-158B-4390-A921-A385AABDE052
P2860
Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Triple-negative breast cancer: ...... a high risk of early relapse.
@en
Triple-negative breast cancer: ...... a high risk of early relapse.
@nl
type
label
Triple-negative breast cancer: ...... a high risk of early relapse.
@en
Triple-negative breast cancer: ...... a high risk of early relapse.
@nl
prefLabel
Triple-negative breast cancer: ...... a high risk of early relapse.
@en
Triple-negative breast cancer: ...... a high risk of early relapse.
@nl
P2093
P1476
Triple-negative breast cancer: ...... a high risk of early relapse.
@en
P2093
Anne de Roquancourt
David Groheux
Elif Hindié
Laetitia Vercellino
Marc Espié
Michel Marty
Nathalie Berenger
Sylvie Giacchetti
P304
P356
10.2967/JNUMED.111.094045
P407
P577
2012-01-12T00:00:00Z